A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Ibrutinib
Related studies linked through entity extraction aliases.
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
- Status
- COMPLETED
- Phase
- PHASE1
Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Study of Ibrutinib in Subjects With Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE3
Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants
- Status
- COMPLETED
- Phase
- PHASE1
Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
- Status
- COMPLETED
- Phase
- PHASE1
A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- Status
- COMPLETED
- Phase
- PHASE3